Company profile: AstraZeneca
1.1 - Company Overview
Company description
- Provider of biopharmaceutical research, development, manufacturing, and marketing of prescription medicines across oncology; cardiovascular, renal and metabolism; respiratory and immunology; vaccines and immune therapies; and rare diseases. Portfolio includes therapies such as datopotamab deruxtecan for advanced nonsquamous non-small cell lung cancer, with clinical trial survival benefits.
Products and services
- Cardiovascular, Renal and Metabolism (CVRM): Develops evidence-based treatments targeting heart, kidney, and metabolic disorders, producing effective prescription medicines designed to improve health outcomes and quality of life
- Datopotamab Deruxtecan: Delivers clinical-trial-backed therapy for advanced nonsquamous non-small cell lung cancer, demonstrating survival benefits in studies for patients with this specific indication
- Oncology: Engineers prescription-grade cancer treatments across diverse tumor types, aiming to improve patient outcomes through innovative therapies that offer added benefits such as reduced side effects
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AstraZeneca
HRA Pharma
HQ: France
Website
- Description: Provider of drugs, devices, and services in reproductive health and endocrine diseases, offering products such as Norlevo for emergency contraception; Cicatridine for vaginitis and vaginal injury; Delidose, Divina, and Duova for hormone replacement therapy; and GyMiso for cervical ripening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HRA Pharma company profile →
Athersys
HQ: United States
Website
- Description: Provider of an adult-derived, off-the-shelf stem cell therapy platform, MultiStem, for neurological, inflammatory and immune, cardiovascular, and other critical care indications. Conducts clinical trials and programs including MASTERS-2 and TREASURE for stroke, and AMI, PVD, and congestive heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Athersys company profile →
DiaMedica Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on treatments for stroke, developing DM199, a recombinant human tissue kallikrein-1 (KLK1) intended to treat acute ischemic stroke and cardio-renal diseases by restoring KLK1 levels, and conducting the ReMEDy2 adaptive, randomized, double-blind, placebo-controlled trial to study DM199’s efficacy and safety in acute ischemic stroke.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DiaMedica Therapeutics company profile →
Zealand Pharma
HQ: Denmark
Website
- Description: Provider of peptide-based medicines and novel specialty drug candidates, leveraging leading-edge expertise and partnerships. Offerings include dasiglucagon for severe hypoglycemia (with Novo Nordisk), survodutide for obesity and MASH (with Boehringer Ingelheim), dapiglutide, and devices such as the investigational bihormonal iLet bionic pancreas (with Beta Bionics) and a continuous infusion pump for congenital hyperinsulinism (with DEKA Research).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zealand Pharma company profile →
Sunovion
HQ: United States
Website
- Description: Provider of therapeutic products discovered, developed and commercialized for central nervous system and respiratory disorders and other illnesses. Portfolio includes Latuda for schizophrenia and bipolar depression; Aptiom for partial-onset seizures; Gemtesa/vibegron for overactive bladder; Myfembree for heavy menstrual bleeding due to uterine fibroids; Orgovyx for advanced prostate cancer; LUNESTA; and XOPENEX.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sunovion company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AstraZeneca
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AstraZeneca
2.2 - Growth funds investing in similar companies to AstraZeneca
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AstraZeneca
4.2 - Public trading comparable groups for AstraZeneca
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →